This prospective, randomly assigned, controlled clinical trial aims to measure the how well it works of ultrasound-guided thoracolumbar fascia (TLF) injection as an adjunct to standard conservative treatment in patients with type 2 diabetes mellitus and chronic nonspecific low back pain. A total of 60 patients aged 18-65 years, diagnosed with type 2 diabetes mellitus for at least one year and experiencing chronic nonspecific low back pain for at least three months, will be enrolled.
Official registry: https://clinicaltrials.gov/study/NCT07927530 · Hatice Zehra FERHATLAR · enrollment listed as 60
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Ultrasound-Guided Thoracolumbar Fascia Injection, or Standard Conservative Treatment. The registry lists allocation as randomized. This prospective, randomly assigned, controlled clinical trial aims to measure the how well it works of ultrasound-guided thoracolumbar fascia (TLF) injection as an adjunct to standard conservative treatment in patients with type 2 diabetes mellitus and chronic nonspecific low back pain.
They plan to enroll about 60 people at Küçükçekmece. Taking part typically means following a program (exercise, therapy, diet, or an app), a procedure as part of the study plus check-ins.
Efficacy of Ultrasound-Guided Thoracolumbar Fascia Injection in the Treatment of Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Interventions: Ultrasound-Guided Thoracolumbar Fascia Injection, Standard Conservative Treatment
Primary outcome (registry wording): Change in Low Back Pain Intensity Measured by the Numeric Rating Scale (NRS)
Hatice Zehra FERHATLAR, MD
haticezehraferhatlar@gmail.com
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.
NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.
NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.
NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary